Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 01, 2015 7:03 PM ET

Personal Products

Company Overview of ISDIN, S.A.

Company Overview

ISDIN, S.A., a pharmaceutical company, researches, develops, and distributes various solutions for dermatology conditions and related needs. The company provides solutions for baby care, dry skin, oral health, greasy skin and dandruff, women health, skin care, atopic skin, hair loss, acne, psoriasis, hygiene, mycosis, bacterial infections, dermatitis, hydric deficit, and photosensitivity needs. It offers fusion fluids, gel cream dry touch products, oil free sunscreen compact make-up products, pediatrics gel creams, fusion gels, lotion sprays, anti-wrinkle creams, actinic keratosis and non-melanoma skin cancer prevention creams, body hydration and hygiene products, facial hydration creams, an...

Provençals 33

Barcelona,  08019


Founded in 1975


34 93 240 20 20


34 93 202 09 80

Key Executives for ISDIN, S.A.

ISDIN, S.A. does not have any Key Executives recorded.

ISDIN, S.A. Key Developments

Mayne Pharma Group Ltd Signs SUBACAP Distribution Agreements with ISDIN and Glenmark

Mayne Pharma Group Ltd. has signed two marketing and distribution agreements with ISDIN and Glenmark for SUBACAP, an improved formulation of itraconazole used to treat fungal infections. The execution of these agreements follows an extensive search and selection process for partners that have the infrastructure, knowhow and track record to successfully commercialise SUBACAP. ISDIN will market the product in Spain, Italy and Portugal. Glenmark will market the product in the United Kingdom. Under the two exclusive distribution agreements, Mayne Pharm will receive upfront payments, milestone payments upon meeting certain market launch hurdles, and a percentage of net sales in each country. Mayne Pharma will manufacture the product for both distributors at its facility in South Australia. Product launch is expected to occur by the end of calendar 2013 in the UK, early 2014 for Spain and by the end of 2014 for Italy and Portugal following a 'repeat use' procedure to extend the existing marketing authorisation into those additional countries.

Similar Private Companies By Industry

Company Name Region
Johnson & Johnson S.A. Europe
Postquam Cosmetic, S.L. Europe
Jesús del Pozo S.A. Europe
Grupo Boniquet Sparchim S.A. Europe

Recent Private Companies Transactions

September 2, 2014
Auriga International
September 1, 2014
Auriga International

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISDIN, S.A., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at